SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences’ Amplitude secures CE mark for robotic surgical system

13 Nov 2025 Evaluate

Zydus Lifesciences’ step-down wholly owned subsidiary -- Amplitude Surgical (Amplitude) has secured CE mark approval for its proprietary robotic surgical system ‘Andy’. This confirms its compliance with European standards for safety, performance, and quality. Andy is built with its proprietary navigation platform, Amplivision. The CE-marked solution integrates Amplitude’s navigation technology with robotic assistance, developed through a strategic collaboration with eCential Robotics. Amplitude Surgical (Amplitude) is a wholly owned subsidiary of Zydus MedTech France SAS, a wholly owned subsidiary of the company.

The Andy robotic surgical system marks a significant advancement in orthopaedic surgery. Conceived as a true surgical partner, Andy is a collaborative robot built on proprietary technology capable of performing bone resections with precision and reliability. This innovation empowers surgeons with greater confidence in the operating room and sets a new benchmark for robot-assisted procedures across Europe. Andy delivers enhanced accuracy and consistency, enabling optimal alignment while minimizing tissue trauma which is intended to result in smaller incisions, reduced pain, faster recovery, and fewer complications, ultimately enhancing knee function, shortening hospital stays, and ensuring long-term implant performance.

Earlier this year, Zydus MedTech expanded its global presence with the strategic acquisition of Amplitude Surgical a European MedTech company specializing in high-quality lower-limb orthopaedic technologies. This acquisition strengthens Zydus MedTech’s goal of delivering advanced, patient-focused solutions through cutting-edge research, design innovation, and precision engineering.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Zydus Lifesciences Share Price

942.55 3.35 (0.36%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×